NYSE:NVOPharmaceuticals
Novo Nordisk Warning Tests Valuation As Pricing And Competition Intensify
Novo Nordisk (NYSE:NVO) has warned of a potential decline in sales and profit in 2026, citing intensifying US price pressures and upcoming patent expiries.
The company highlighted rising competition in obesity and diabetes treatments, particularly in the GLP-1 segment, as a key headwind.
Management changes, including the departure of the US chief, are occurring alongside a renewed focus on rolling out new products and expanding in select markets.
Novo Nordisk enters this period of pressure...